2010
Time-Lag Bias in Trials of Pediatric Antidepressants: A Systematic Review and Meta-Analysis
Reyes MM, Panza KE, Martin A, Bloch MH. Time-Lag Bias in Trials of Pediatric Antidepressants: A Systematic Review and Meta-Analysis. Journal Of The American Academy Of Child & Adolescent Psychiatry 2010, 50: 63-72. PMID: 21156271, PMCID: PMC3645909, DOI: 10.1016/j.jaac.2010.10.008.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitorsPlacebo-controlled trialTime-lag biasMajor depressive disorderYears of ageReuptake inhibitorsAntidepressant trialsPediatric depressionDepressive disorderTreatment respondersMAIN OUTCOMESystematic reviewMeta-AnalysisPositive findingsNegative findingsNegative trialsMedical literatureAntidepressantsTrialsPublication of findingsNegative resultsChild psychiatryEfficacyFindingsPublication time
2006
Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study
Tierney E, Aman M, Stout D, Pappas K, Arnold LE, Vitiello B, Scahill L, McDougle C, McCracken J, Wheeler C, Martin A, Posey D, Shah B. Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study. Psychopharmacology 2006, 191: 149-157. PMID: 17123125, DOI: 10.1007/s00213-006-0604-z.Peer-Reviewed Original ResearchConceptsClinical trialsClinical trial proceduresParent satisfactionDouble-blind clinical trialRandomized clinical trialsTrial proceduresResearch participationClinical responseAcute trialTreatment outcomesActive drugSimilar childrenStudy proceduresTrialsPharmacological researchAutistic disorderLearning TestPlaceboChildren's research participationEthnic minority subjectsChildrenRisperidoneWhite participantsGood allianceDrugs
2005
Risperidone for the Core Symptom Domains of Autism: Results From the Study by the Autism Network of the Research Units on Pediatric Psychopharmacology
McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B. Risperidone for the Core Symptom Domains of Autism: Results From the Study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal Of Psychiatry 2005, 162: 1142-1148. PMID: 15930063, DOI: 10.1176/appi.ajp.162.6.1142.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntipsychotic AgentsAutistic DisorderChildCommunication DisordersConduct DisorderDouble-Blind MethodFemaleHumansInterpersonal RelationsMalePersonality InventoryPlacebosPsychiatric Status Rating ScalesRisperidoneStereotyped BehaviorStereotypic Movement DisorderTreatment OutcomeConceptsYale-Brown Obsessive Compulsive ScaleChildren's Yale-Brown Obsessive Compulsive ScaleRitvo-Freeman Real Life Rating ScaleObsessive Compulsive ScaleBehavior domainsVineland Adaptive Behavior ScalesCompulsive ScaleCore symptom domainsAdaptive Behavior ScalesSensory-motor behaviorsSelf-injurious behaviorCommunicative impairmentsAutistic childrenSocial relatednessAutism NetworkRating ScaleCommunication impairmentsSevere tantrumsCore symptomsBehavior ScaleSocial interactionAutistic disorderAutismSymptom domainsLife Rating ScaleChild Psychopharmacology, Effect Sizes, and the Big Bang
Martin A, Gilliam WS, Bostic JQ, Rey JM. Child Psychopharmacology, Effect Sizes, and the Big Bang. American Journal Of Psychiatry 2005, 162: 817-a-817. PMID: 15800175, DOI: 10.1176/appi.ajp.162.4.817-a.Peer-Reviewed Original Research
2003
Which SSRI? A Meta-Analysis of Pharmacotherapy Trials in Pediatric Obsessive-Compulsive Disorder
Geller DA, Biederman J, Stewart SE, Mullin B, Martin A, Spencer T, Faraone SV. Which SSRI? A Meta-Analysis of Pharmacotherapy Trials in Pediatric Obsessive-Compulsive Disorder. American Journal Of Psychiatry 2003, 160: 1919-1928. PMID: 14594734, DOI: 10.1176/appi.ajp.160.11.1919.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsObsessive-compulsive disorderStandardized mean differenceOutcome measuresMean differenceStudy designSerotonin reuptake inhibitorsDependent outcome measuresAdolescent obsessive-compulsive disorderSystematic literature searchMultivariate regression analysisPediatric obsessive-compulsive disorderTypes of drugsEffect sizePlacebo treatmentMedication trialsReuptake inhibitorsOutcome scoresPharmacological treatmentPharmacotherapy trialsOverall effect sizeInclusion criteriaClinical careDrug effectsMeta-AnalysisLow-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study
Martin A, Koenig K, Anderson GM, Scahill L. Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study. Journal Of Autism And Developmental Disorders 2003, 33: 77-85. PMID: 12708582, DOI: 10.1023/a:1022234605695.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderSelective serotonin reuptake inhibitor responseOpen-label studyOpen-label trialLow-dose fluvoxamineDevelopmental disordersPremature discontinuationClinical responseFluvoxamine treatmentPartial respondersMean ageSerotonin levelsSelect childrenPubertal statusInhibitor responseBehavioral activationFluvoxamineChildrenFurther investigationDisordersTreatmentGender differencesAdolescentsSubjectsTolerability
2002
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D. Risperidone in Children with Autism and Serious Behavioral Problems. New England Journal Of Medicine 2002, 347: 314-321. PMID: 12151468, DOI: 10.1056/nejmoa013171.Peer-Reviewed Original ResearchConceptsClinical Global Impression-ImprovementAtypical antipsychotic agentsPlacebo groupSelf-injurious behaviorRisperidone groupAntipsychotic agentsAutistic disorderIrritability scoresDouble-blind trialPrimary outcome measureTreatment of adultsTraditional antipsychotic medicationsPercent decreaseSerious behavioral disturbancesAberrant Behavior ChecklistRisperidone therapyTardive dyskinesiaAntipsychotic medicationAverage weight gainOutcome measuresPositive responsePostsynaptic dopamineSerotonin receptorsBehavioral disturbancesSevere tantrums
2001
SMITH-LEMLI-OPITZ SYNDROME
Martin A, Koenig K, Scahill L, Tierney E, Porter F, Nwokoro N. SMITH-LEMLI-OPITZ SYNDROME. Journal Of The American Academy Of Child & Adolescent Psychiatry 2001, 40: 506-507. PMID: 11349693, DOI: 10.1097/00004583-200105000-00008.Peer-Reviewed Original Research
2000
Assessment in Multisite Randomized Clinical Trials of Patients with Autistic Disorder: The Autism RUPP Network
Arnold L, Aman M, Martin A, Collier-Crespin A, Vitiello B, Tierney E, Asarnow R, Bell-Bradshaw F, Freeman B, Gates-Ulanet P, Klin A, McCracken J, McDougle C, McGough J, Posey D, Scahill L, Swiezy N, Ritz L, Vokmar F. Assessment in Multisite Randomized Clinical Trials of Patients with Autistic Disorder: The Autism RUPP Network. Journal Of Autism And Developmental Disorders 2000, 30: 99-111. PMID: 10832774, DOI: 10.1023/a:1005451304303.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsAutistic DisorderChildHumansNeuropsychological TestsReproducibility of ResultsRisperidoneTreatment OutcomeConceptsAutism Diagnostic InterviewChildren/adolescentsAutistic disorders symptomsNeuropsychological testsDisorder symptomsLower functioningAutistic disorderCore featuresTest developersDiagnostic InterviewProblem presentationPediatric psychopharmacologyAutismIndividual changesTreatment respondersTarget symptomsSecondary symptomsCommunication problemsMethodological challengesAssessment strategiesSubject heterogeneityIQPharmacological treatmentDisordersClinical Global ImpressionPharmacotherapy of Early-Onset Depression Update and New Directions
Martin A, Kaufman J, Charney D. Pharmacotherapy of Early-Onset Depression Update and New Directions. Child And Adolescent Psychiatric Clinics Of North America 2000, 9: 135-157. PMID: 10674194, DOI: 10.1016/s1056-4993(18)30139-1.Peer-Reviewed Original ResearchConceptsEarly-onset depressionDepressive disorderSafety dataLong-term exposureBrain-derived neurotrophic factor levelsLong-term safety dataEarly-onset depressive disordersAvailable antidepressant agentsRigid treatment guidelinesUseful treatment interventionsNeurotrophic factor levelsLong-term followShort-term efficacyShort-term efficacy dataAtrophic brain changesHigh recurrence ratePsychopharmacology Algorithm ProjectRoutine clinical practiceAlternative treatment strategiesYears of ageShort-term trialsPaucity of dataRisk-benefit analysisLong-term useAntidepressant medication